Dowlais Group Aktie 125501393 / GB00BMWRZ071
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
27.10.2025 14:39:35
|
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
|
The Vanguard Group, Inc. ( )
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
(b) Cash-settled derivative transactions
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
(ii) Exercise
(d) Other dealings (including subscribing for new securities)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
(b) Agreements, arrangements or understandings relating to options or derivatives
(c) Attachments
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Category Code: | RET - Dowlais Group plc |
| TIDM: | |
| LEI Code: | 5493002789CX3L0CJP65 |
| Sequence No.: | 406336 |
| EQS News ID: | 2219182 |
| End of Announcement | EQS News Service |
|
|
Nachrichten zu Dowlais Group PLC Registered Shs
|
05.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
03.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
31.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
30.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
28.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
27.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
24.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) | |
|
23.10.25 |
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc (EQS Group) |
Analysen zu Dowlais Group PLC Registered Shs
Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer
Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉
Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.
💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zahlenflut im Blick: SMI und DAX letztlich schwächer -- US-Börsen gaben nach -- Märkte in Fernost legten kräftig zuAm Donnerstag zeigte sich der heimische Aktienmarkt mit Abgaben, während der deutsche Leitindex in der tiefroten Zone verharrte. An der Wall Street wurden Verluste beobachtet. Unterdessen ging es an den asiatischen Aktienmärkten klar nach oben.


